DT News - UK - Straumann celebrates 20th anniversary of Emdogain at EuroPerio8

Search Dental Tribune

Straumann celebrates 20th anniversary of Emdogain at EuroPerio8

Clinical experts discussing clinical applications and the future of Emdogain. (Photograph: Kristin Hübner, DTI)

Fri. 5 June 2015

save

LONDON, UK/BASEL, Switzerland: Straumann invited leading dental professionals from around the world to celebrate the 20th anniversary of its cornerstone regenerative product Emdogain, at EuroPerio8 in London. First marketed in Sweden in 1995, Straumann Emdogain is still the standard treatment for the regeneration of periodontal hard and soft tissue that is lost due to periodontitis.

Improving patient comfort and treatment safety are priorities in periodontology and are reflected in the increasing trend toward minimally invasive procedures. Emdogain is particularly advantageous in this regard, as it is associated with less pain and swelling and fewer complications than treatment with membranes after surgery.

While products such as membranes work on a mechanical principle, Emdogain is a biologically-active, protein-based gel that induces periodontal regeneration, reinitiating processes in adults that occur naturally in the human body during tooth development. This mechanism of action enables periodontists to maintain soft tissues and, more importantly, to regenerate lost periodontal tissues, aiding in the prevention of tooth loss.

Even after 20 years on the market, Emdogain has not been surpassed by any other technologies and it still remains the gold standard in periodontal tissue regeneration. Backed by more than 950 peer-reviewed publications and 500 human studies, Emdogain is one of the most extensively investigated products in dentistry. The product became the cornerstone of Straumann’s regenerative business in 2003, when the company acquired Biora AB. Since then, based on the volumes sold to date, more than two million patients have been treated worldwide with Emdogain.

Marco Gadola, CEO of Straumann, commented: “We are proud to have a product that has helped restore the confidence of countless people who would have lost teeth because of periodontitis. Emdogain is unique and we believe that the most exciting chapter of its history is yet to be written. Recent findings have inspired further development in several indications, including enhanced bone healing and maturation. Here, we are working to launch Straumann Osteogain, a liquid formulation for the combination with bone substitutes, later this year.”

To celebrate the 20th anniversary of Emdogain during EuroPerio, Straumann brought together some of the most renowned clinicians to discuss its past, present and future role in the field of periodontal regeneration. The event was hosted by Prof. Bjarni Elvar Pjetursson, Head of Reconstructive Dentistry at the Faculty of Odontology of the University of Iceland. The podium discussion was recorded on video and will be available at www.youtube.com/StraumannGlobal.

Headquartered in Basel, Switzerland, the Straumann Group is a global leader in implant, restorative and regenerative dentistry. Including its Neodent business, the Group currently employs approximately 3500 people worldwide and its products and services are available in more than 70 countries.

To post a reply please login or register
advertisement
advertisement